RepliCel Life Sciences Inc. (REPCF)

[LongRun8]

News out:

http://www.otcmarkets.com/stock/REPCF/news

Replicel and Shiseido Announce Collaboration and Technology Transfer Framework Agreement and Exclusive Geographic Technology License

TOKYO, JAPAN AND VANCOUVER, BRITISH COLUMBIA, May 29, 2013 (Marketwired via COMTEX) -- RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF)(CNSX: RP) and Shiseido Company, Limited ("Shiseido") (TSE: 4911)(PINKSHEETS: SSDOY) announced today that they have entered into a Collaboration and Technology Development Transfer Framework Agreement ("the Agreement") for an exclusive geographic license for RepliCel's RCH-01 hair regeneration technology. Under the final agreement, Shiseido will pay RepliCel an upfront fee of yen 400,000,000. In addition, Shiseido will pay RepliCel sales milestones up to yen 3,000,000,000. Replicel is also entitled to royalties on sales.

David Hall, CEO and President of RepliCel states, "Shiseido is one of the oldest and most respected cosmetics companies in the world with annual sales in excess of US$6.7 billion. Since its inception in 1872, they have stood at the forefront of science, innovation and beauty. They are known throughout the industry for their research and development in skin and hair biology as well as expertise in formulation and manufacturing. This Agreement for our RCH-01 autologous cell therapy for pattern baldness is consistent with our goal to partner with the leading companies in the field of hair regeneration. The Agreement also represents a key validation of our technology platform being built around the concept of addressing cellular deficits in human conditions."

"Shiseido's corporate mission is a research driven focus on human beauty and wellness," stated Mr. Youchi Shimatani, Shiseido's corporate officer in charge of research and development. "Our hair cell related research is to support those people suffering with pattern baldness. With this focus, I am delighted to be entering into a technical partnership with RepliCel which is a leader in hair regenerative technology," concluded Mr. Shimatani.

Professor Rolf Hoffmann, RepliCel's Chief Medical Officer commented, "The Agreement will ultimately see further human clinical trials being conducted by Shiseido in its territory. In addition, the Agreement anticipates ongoing research collaboration for the continued improvement of the technology. As Shiseido has world-class technical expertise in hair biology, we anticipate that together we will develop further improvements to the technology. As a co-founder of the Company, I am extremely pleased to be partnering with a leader in hair science."

RCH-01 is a patented hair follicle cell replication and implantation technology designed to rejuvenate damaged, miniaturized hair follicles in balding scalp skin. This technology has been developed over ten years of research, experimentation and trials. The mechanics of this technology involve the extraction of as few as 20 hair follicles from the back of a patient's scalp where healthy cycling hair follicles reside. Specific cells are isolated from the hair follicles and are then replicated in a current Good Manufacturing Practice compliant facility through the Company's proprietary cellular replication process, and are then reintroduced back into balding areas on a patient's scalp. The implanted cells are expected to rejuvenate damaged hair follicles leading to the growth of new healthy hair fibers.

"The Shiseido agreement represents another significant step in the development of RCH-01", stated Dr. Kevin McElwee, Chief Scientific Officer. "We are excited to be collaborating with such a skilled group of scientists."

The Agreement encompasses a geographic area including Japan, China, South Korea, Taiwan and the ASEAN countries representing a population of approximately 2.1 Billion people. Joint steering committees will be established to oversee the transfer of the technology, knowhow and standard operating procedures.

About RepliCel Life Sciences

The Company is developing two autologous cell therapies. The first is a cellular treatment for androgenetic alopecia (pattern baldness) named RepliCel Hair-01 (RCH-01). The second is a cell therapy for the treatment of chronic tendon injuries named RepliCel Tendon-01 (RCT-01). Both treatments are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. Phase II clinical trials, for both technologies, are planned for the later part of 2013.

About Shiseido Company, Limited

Shiseido started business in Ginza, Tokyo in 1872 as the first Western-style pharmacy in Japan. Since then, the company has led the cosmetic technology and culture in Japan over more than 100 years. The company now aspires to become a "global player to represent Asia with origins in Japan" and operate businesses all over the world, including Europe, the U.S. and Asia. Its representative global brand, "SHISEIDO" is now sold in 89 countries and regions as of April 2013.

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and include the following: (i) that the Company and Shiseido will enter into a definitive license agreement for an exclusive geographic license for RepliCel's RCH-01 hair regeneration technology and receive the payments set out above; (2) that the Company will partner with the leading companies in the field of hair regeneration, including Shiseido; (3) that the Company will ultimately see further human clinical trials being conducted; (4) that ongoing research collaboration will be conducted by the Company and Shiseido for the continued improvement of the technology; (5) that the Company and Shiseido will develop further improvements to the technology; (6) that the Company's technology will rejuvenate damaged hair follicles leading to the growth of new healthy hair fibers; and (7) Phase II clinical trials, for both the hair technology and the tendon technology, will be conducted in the later part of 2013. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: that the Company and Shiseido may not be able to negotiate and enter into a definitive license agreement pursuant to which the Company will license to Shiseido an exclusive geographic license for RepliCel's RCH-01 hair regeneration technology; that the Company and Shiseido may not be able to agree on the research and development to be conducted in connection with the Company's technology; that negative results from the Company's clinical trials may impact further trials and development of the technology; the effects of government regulation on the Company's business, including the future development of the technology; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance.

Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2012 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on Sedar at www.sedar.com.

Contacts:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
[e-mail]
www.replicel.com

Shiseido Company, Limited
Tatsuyoshi Endo
Public Relations Department
[phone]
[e-mail]
www.shiseido.com


SOURCE: RepliCel Life Sciences Inc. and Shiseido Company, Limited

CONTACT: mailto:[e-mail]
http://www.replicel.com
mailto:[e-mail]
http://www.shiseido.com

(C) 2013 Marketwire L.P. All rights reserved.

-0-

SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Trials

[LongRun8]

Anyone of the few followers of this stock out there know any recent news regarding their study progress? I have been sitting on this stock for some time now without any news from the company. I really want to just make my money back (or sell for a little loss, if necessary) on this stock and get out if there is no hope on the horizon.

[buffalosabres12]

Underwhelming/bleh results. Better than nothing I guess. Current price is probably about fair value.

[paulyb]

See pr for positive results on REPCF.

[jjj373]

Yet another TOBIN SMITH FLOP in the making!

[paulyb]

I just spoke with Tammi in investor relations. A pr was expected to coincide w/the article that was written. The co. makes it clear that it wants no part of a pnd type campaign but the test results will probably be announced within the next 2 days. @.8mil was just raised and the co. is in good shape. I panicked this am also because I own a decent block. I am satisfied and will buy addl.

[mindonmymoney]

Buyer BEWARE! I purchased some of this stock and was going to try to sell it this morning after seeing that the company was retracting some of its own disclosures, but good luck with it down $0.65 on the day so far...

I have some friends in the business in Vancouver and did some asking around and it looks like somename named Abeir is behind this deal...does anyone else know him or anything more about this company?

This is a joke...$100 Million market cap?? This thing should have a $10 million cap at best, its only in phase 2 development and has no assets or money in the bank..good luck trying to make a buck on this, unless youre in it for the long run ( 10 years is my guess ) stay away!

[paulyb]

The co. had to retract an opinion that they paid for but freaked out when they read it. They had to come out with some cya verbage. Quit dumping and all of this will go away,

[buffalosabres12]

Where have you heard they are raising money at $.50/share?

[Darkhorse69]

I cant believe my eyes...I had thought this one may have had a shot but you are all right...there must be some scumbag behind this trying to "get rich or die trying" at retail investors expense....all out there reading this that have the ability( as I do not ), please get this message on every board out here and do the investing public a favor. Rumor has it they are raising money at .50 and selling all day to guys like me that bought at 2.50 a share, only up 500% from where buddies and pals are buying in?!?!. This is going to the SEC, immeadiately. enough of the blatent scams.

100m$ mcap only in phase 2? Im sure the price of this stock was manipulated higher.....the professionals behind the actual business and technology, that engaged these people should not only fire them but report them before they go down with their own ship.

Terrible stuff, Im selling Monday morning and going short if I can.

If anyone knows who's behind this you should post it publically and report it. I really hate the OTC/BB

[ErnieBilco]

I think the lawyers are ready to pounce on this pump and dump operation, an SEC halt would not be out of the question either.

24 emails
$180K paid for pumps
http://newsletter.hotstocked.com/stocks/view/REPCF-RepliCel-Life-Sciences-Inc.

Result= A worthless POS company who just orchestrated a fraud on the investors who didn't see beyond the pump - Monday will be the dump.

Jail time is needed for the insiders who approved and paid for this fraud..... the promoters also need jail time for their publishing fairytale price targets and fluffed up claims....hiding behind a disclaimer should not allow these pump and dump operators from being held financially liable for their lies and falsehoods.

JMO

[buffalosabres12]

My guess in the company is DOA. If the trial was successful, the wouldn't need to retract those statements, because those statements would have likely have been truth. I wouldn't be surprised to see a lawsuit if the trials come up real bad. Replicel has been buying those paid pump articles for a couple of weeks now, and they have been analyzing trial results for over a month now, so they've known for a while what's it's true efficacy is. So if they were paying for pump pieces saying that it's a billion dollar cure, all the while knowing the true lack of efficacy of their treatment, and then waiting until after hours on the Friday before the Monday their results are (presumed) to be released on, while they had 2 weeks to retract the statements, but since the ads have been running they have seen a substantial run up in price, all the while trapping in hundreds of retail investors and desperate bald men, only to drop the bomb on them on Monday.

Some lawyer will have a field day with that.

[paulyb]

I see no posts in 2 days. I would like some conversation concerning the co. and it's disclaimer posted fri.

[MullItOver]

Ugh. Didn't see much action so I sold.

[Corvette1]

I got the pump email from BeaconEquity today.

[MullItOver]

Looking good here!

[Dyson]

REPCF is ready for a monster run today!

Are you ready for the next hot one? REPCF - RepliCel Life Sciences Inc. is developing a scientific technology that has the potential to become the world's first, minimally invasive, permanent solution for hair loss in men and women.
That’s why I’m so excited to tell you about this company that provide a very effective solution to hair loss.
The procedure REPCF invented is the one that has been in development over the past nine years by the company's research scientists and medical experts, and is currently undergoing phase I/IIa clinical trials in Europe.
There’s a lot of amazing things going on with REPCF so I'll go straight to the point to keep it from getting too confusing. The potential of this company is enormous, since its technology seems like it is in huge demand today!
I think REPCF is getting the attention of the Street today and you should take a close look at this one immediately.
REPCF is in a huge market!
The American Academy of family Physicians estimates the US market for non-surgical hair treatment s at over $1 Billion annually. This is huge! REPCF is getting the attention of the Street today and I encourage my members to take a close look at this one to be ready for a new action!
Efforts are now focused on ensuring the safety and demonstrating the efficacy of RepliCel’s cell-based hair regeneration procedure in humans. The long-term goal is the development of a safe, evidence-based, minimally invasive procedure to treat various types of hair loss in men and women.
A very impressive management team!
RepliCel was founded by a group of scientists and dermatologists from recognized academic research institutions with experience in immunology, hair biology, hair growth, alopecia, hair follicle endocrinology and morphogenesis, and clinical dermatology. Each scientist holds a long-established track record of research productivity. http://www.replicel.com/our-science/scientific-medical-team/
REPCF was founded to advance the breakthrough findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, Drs. McElwee and Hoffmann discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals. REPCF is now developing this discovery as a potential treatment for hair loss in humans.

In addition to the discovery of the critical cell population, RepliCel has created a proprietary method for extracting and, replicating dermal sheath cup cells, with the goal of developing a safe minimally invasive procedure for inducing natural hair growth in men and women suffering from various types of hair loss. The procedure has shown promise in pre-clinical trials, based on tissue engineering and laboratory models.
Translating Findings Into a Potential Hair-Loss Solution

Based at established universities in Canada and Germany, RepliCel’s scientific founders and research scientists have studied immunology, hair biology and hair growth for more than two decades. This respected team has developed a strong scientific understanding of the mechanisms underlying alopecia.
RepliCel’s current research activity is aimed at translating the scientific discoveries made by research scientists Drs. Kevin McElwee and Rolf Hoffmann. The scientists found that dermal sheath cup-derived cells induced the formation of new hair follicles in purpose-bred mice. The study suggested that dermal sheath cup cells were the reservoir of mesenchymal stem cells that were responsible for the continued cycling of the hair follicle, as well as neogenesis of new hair follicles.

This discovery provided the basis for patent applications beginning in 2003. Patents are now issued in Europe and Australia and are pending in the US, Canada, and Japan.
To learn more please read our scientist’s published paper in The Journal of Investigative Dermatology http://www.nature.com/jid/journal/v121/n6/full/5602058a.html

The procedure is now undergoing further rigorous study to establish safety and determine effectiveness. The first human clinical trial (Phase I/IIa) began in the country of Georgia in December 2010. Further clinical trials are planned for 2012 in European and/or North America.
Human clinical trials are now underway to translate RepliCel’s fundamental scientific findings into a safe and effective minimally invasive solution for treating androgenetic alopecia and other forms of hair loss in men and women.
There’s a lot of amazing things going on with REPCF so I'll go straight to the point to keep it from getting too confusing. The potential of this company is enormous, since its technology seems like it is in huge demand today!
That means REPCF stays diverse and isn't as vulnerable to the up and down swings of one industry.
This is a company that has found a new way to make huge benefit for both men and women! This new hair loss recovery technology could be far more efficient, and this may make traders go absolutely insane for REPCF causing some potentially enormous gains.
Their site has a great video explaining it and a lot of good info: http://www.replicel.com/
REPCF looks like the hot play for Tuesday morning!
Watch it very closely.

[expressman]

One of the few stocks I've seen on this site that may have some real potential.

[grnbkrboy]

Replicel onto cure for baldness...upcoming FDA review

hearing their technology is working. FDA review coming up in April.

http://www.nbtequitiesresearch.com/report/great-interview-wreplicel-ceo-on-ending-world-baldness

[bell345]

Toby pumping this (paid research):

http://nbtequitiesresearch.com/sites/default/files/uploads/20111204_NBT_EQUITY_GROUP_REPLICEL_LIFE_SCIENCE_REPORT.pdf

[TradeBaron]

Replicel in the news:
http://editorial.equities.com/spotlight-companies/replicel-converts-class-c-shares-to-common-stock/

[TradeBaron]

REPCF hair follice implants work on mice!

Chief Medical Officer for Replicel discusses company's success:
http://editorial.equities.com/spotlight-companies/rolf-hoffmann-chief-medical-officer-replicel-life-sciences/

[ICEQUITY]

Interview with Dr. Rolf Hoffman, Chief Medical Officer for Replicel Life Sciences:
http://editorial.equities.com/spotlight-companies/rolf-hoffmann-chief-medical-officer-replicel-life-sciences/

[ICEQUITY]

Replicel provides update on Corporate activity:
http://repcf.equities.com/pr/rep/test-218251.aspx

Quote:
http://www.equities.com/summary?s=repcf

[ICEQUITY]

Replicel (REPCF) developing a cell-based solution to hair baldness...
http://www.equities.com/summary?s=repcf

[ICEQUITY]

S&P's Latest Stock Report on Replicel Life Sciences
http://www.equities.com/news/news-story?val=166735098

[Editor1]

BioTuesdays: RepliCel’s cell-based solution to hair loss

http://biotuesdays.com/2011/10/18/replicel’s-cell-based-solution-to-hair-loss/

[ICEQUITY]

Replicel's Future and Growth Looking Bright....
"..on the verge of introducing a potential game-changer is RepliCel Life Sciences, Inc. (REPCF), a Vancouver-based company focused on developing a safe and effective cell-based hair regeneration treatment for humans."

http://editorial.equities.com/spotlight-companies/replicel-regenerating-hair-growth/

[ICEQUITY]

@StockNotifier REPCF - John A Barr 11:47am Oct 11 OMG. I will buy every share I can afford, because I KNOW , once FDA approves this, the profit from the pps will pay for the procedure. (being bald sux azz. in my mind anyway)

https://www.facebook.com/groups/itideas/

[ICEQUITY]

RepliCel Life Sciences Inc. (REPCF)Developing a cell-based solution to hairloss